COVID-19 Vaccine Batch Analysis

The variability of quality, including efficacy and adverse events data, of vaccine batches and lots has been controversial during the mass experimental quasi-vaccine program.

See also,

Batch/Lot Analysis

There is substantial debate over a “hot lots” hypothesis that particular batches or lots of COVID-19 vaccines are substantially more toxic than others. Some researchers such as former Pfizer Chief Scientist Michael Yeadon think that there may be bad batches or lots of vaccines, and that this might even be intentional.1) Others such as Jessica Rose and Mathew Crawford think that there are reasonable explanations for the varied data.2)3)

In August 2021, Japan rejected 1.6 million doses of Moderna's vaccine due to contamination with particulate matter, including what seemed like magnetic metals.4)

Preferential Batches for Insiders

There are distinct commercial and clinical processes for producing vaccines as outlined on page 18 in an assessment report by the European Medicines Agency on Pfizer's Comirnaty vaccine.5) Controversially, the superior (clinical) quality vaccines with better testing data were preferentially set aside for Pfizer employees.6) The Therapeutic Goods Administration in Australia outlines such a preferential program with purity and integrity assessments for vaccine batches.7) Vaccine safety researcher Jessica Rose points out that there are no VAERS reports for any of the batches listed by the Australian government.8)